Over the past decade, InnoCare has achieved remarkable results. 2026 marks the beginning of the Company’s next golden decade of development. Driven by its outstanding performance in 2025, the Company ...

RMAT designation is based on promising Phase 2 clinical data demonstrating NG01’s potential to reduce disability and improve function in patients with PMS ...

As both energy prices and inflation fears pop, expectations for Federal Reserve interest rate cuts are sliding. Traders have taken even a September cut off the table and now see only one coming, in ...

When State Rep. James Talarico took the microphone to deliver his victory speech after winning Texas’ Democratic Senate primary this week, he noted that his Republican rivals would likely call him a ...

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...

The Air Force conducted its first test of the Extended Range Attack Munition, a new standoff cruise missile, less than 16 months after awarding its contract. (Air Force) On Jan. 21, the Air Force ...

If you get a pet insurance quote through Progressive you might be sent to a partner company Written By Written by Insurance Writer, Buy Side John was formerly staff writer at Buy Side. Edited By ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...

Russian forces near collapse in Kupyansk as Moscow allies concede city lost: Report America’s biggest oil field is turning into a pressure cooker StubHub apologizes for mix-up involving metal band ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for tolebrutinib is anticipated to be delayed In response to an FDA request, Sanofi has submitted an ...

A new multicenter study led by Mayo Clinic researchers has established a practical, evidence-based definition for rapidly progressive dementia (RPD), a rare but devastating form of cognitive decline ...